Applied Clinical Trials-04-01-2025

View the Applied Clinical Trials April 2025 issue in an interactive format.

Amid new government directives around diversity, equity, and inclusion programs in the US, our April issue explores the pivots and adjustments pharma and healthcare interests are making to maintain the progress of such efforts in advancing clinical research.

Examining the implications of the recent US executive orders concerning diversity, equity, and inclusion pursuits—and the key questions each clinical trial stakeholder must now navigate.

The future of clinical trial design involves incorporating the patient experience into strategic asset planning.

Study uncovers insights on the impact on safety, patient enrollment/retention, and compliance.

The challenges, opportunities, and strategic outlook for oncology research centers.

Anticipating divestment, reallocation of investments, and retrenchment.

The clinical trial industry has a rare opportunity to redefine its role in public health conversations.

Exploring the different stages in the development of a digital measure, and the activities and steps key to achieving meaningful impact for patients.

Why investing in truly effective training from the outset can pay off exponentially for clinical teams—and serve as a strategic advantage.

Clinical trial liaisons rather serve as experts in their therapeutic areas and as clinical trial specialists to provide a suite of strategic advantages to benefit a study.